title: Myeloma: diagnosis complications and supportive care.
abstract: A key approach to current treatment is the rapid reduction of the myeloma clone to minimal disease levels. This approach has significantly improved outcomes but it remains critical to manage the side effects of the disease and of treatment emergent side effects. While  these supportive care options are directed towards improving patient quality of life, they also have significant effect against the disease and can improve survival.
authors.affiliation: Institute of Cancer Research, Brookes Lawley Building,15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK. gareth.morgan@icr.ac.uk
authors.forename: Gareth
authors.initials: G
authors.lastname: Morgan
mesh_terms: D000686:Amyloidosis / Q000209:etiology; D000740:Anemia / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy / Q000209:etiology; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D011719:Pyrazines / Q000627:therapeutic use; D011788:Quality of Life; D051437:Renal Insufficiency / Q000188:drug therapy / Q000209:etiology; D013927:Thrombosis / Q000209:etiology; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007093:Imidazoles; D011719:Pyrazines; D000069286:Bortezomib; D000077211:Zoledronic Acid